Srikiran Pothamsetty, MD
Gastroenterology · Orlando, FLNPI 1821190562
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,000 of the $26,779 with a category attached, or 74.7%. Biotronik Inc. accounts for 74.7% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2020 at $22,968 and has fallen 97.6% since, to $547 in 2025. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $230.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$20K
- AbbVie$5K
- Johnson & Johnson$191
- Celltrion USA Inc.$166
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- Ardelyx, Inc.$131
- plus $1K from 25 others
Across 6 payments — averaging $5293.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$32K
What the payments were for
- Consulting fees$240%
- Speaking & faculty fees$4,40016%
- Grants$20,00075%
- Food & beverage$2,3099%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 1 | $20,000 |
| AbbVie(2 entities) | 32 | $4,901 |
| Johnson & Johnson | 7 | $191 |
| Celltrion USA Inc. | 7 | $166 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Ardelyx, Inc. | 7 | $131 |
| Ironwood Pharmaceuticals, Inc | 2 | $103 |
| Intercept Pharmaceuticals, Inc. | 4 | $93 |
| Merck | 4 | $92 |
| Olympus America Inc. | 1 | $91 |
| Redhill Biopharma Inc. | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Amgen | 2 | $61 |
| QOL Medical, LLC | 3 | $57 |
| Gilead | 4 | $55 |
| Covidien LP | 4 | $54 |
| Lilly USA, LLC | 2 | $51 |
| ASD Specialty Healthcare, LLC | 1 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Vivus LLC | 2 | $36 |
| Evoke Pharma, Inc. | 2 | $31 |
| Novo Nordisk | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Braintree Laboratories, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Bristol Myers Squibb | 1 | $19 |
| Medtronic | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$4,400
How this compares
$26,779 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 224 | $226,528 |
| CreonLipase/Protease/Amylase | 30 | $101,299 |
| IbsrelaTenapanor Hcl | 33 | $56,261 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 555 | $35,142 |
| Mesalamine | 68 | $33,665 |
| ZenpepLipase/Protease/Amylase | 11 | $33,623 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 182 | $30,455 |
| MotegrityPrucalopride Succinate | 34 | $28,118 |
| VemlidyTenofovir Alafenamide | 16 | $22,696 |
| TrulancePlecanatide | 22 | $17,570 |
| MovantikNaloxegol Oxalate | 14 | $7,194 |
| Omeprazole | 629 | $6,843 |
| Famotidine | 466 | $5,734 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 238 | $3,721 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 199 | $3,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $4,901 | $327,827254 claims |
| Ardelyx, Inc.Ibsrela | $131 | $56,26133 claims |
| Aimmune Therapeutics, Inc.Zenpep | $26 | $33,62311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $69 | $28,11834 claims |
| GileadVemlidy | $55 | $22,69616 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $162 | $17,57022 claims |
| Redhill Biopharma Inc.Movantik | $89 | $7,19414 claims |
| Braintree Laboratories, Inc.Sutab | $23 | $2,11413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Orlando
- Samuel GidayOrlando$2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Robert HawesOrlando$377K
- Jason KorenblitOrlando$373K
- Dennis YangOrlando$349K
- Muhammad HasanOrlando$312K
- Kenneth FeuerOrlando$118K
- Ahsan KhanOrlando$98K
- Ilan AharoniOrlando$56K
- Lukasz KwapiszMiami$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.